the antitumour activity of acm in patients with acute lymphoblastic leukaemia or malignant lymphoma who have previously received doxorubicin or daunorubicin is low , and the issue of whether acm lacks clinical cross-resistance to other anthracyclines is unresolved .
C0013089
doxorubicin
C0011015
daunorubicin